Literature DB >> 17920542

Corticosteroids for multiple sclerosis: I. Application for treating exacerbations.

Elliot M Frohman1, Anjali Shah, Eric Eggenberger, Luanne Metz, Robert Zivadinov, Olaf Stüve.   

Abstract

Multiple sclerosis (MS) is an inflammatory demyelinating disorder characterized by a multiphasic course of neurological exacerbations, periods of clinical remission, and, in most patients, ultimately progressive deterioration of functional capabilities. The relapsing-remitting phase of the disease involves acute interruption in neurological functioning relating to areas of inflammation in discrete central-tract systems. The treatment of MS exacerbations with anti-inflammatory agents such as corticosteroids and adrenocorticotropic hormone has represented an established practice throughout the neurology community. Although there is scientific rationale supporting application of these agents for this purpose, the broad diversity of approaches to using these drugs in clinical practice is a derivative of expert opinion and anecdotal experience. Ultimately, the treatment of MS-related exacerbations is part science, but mostly art. This review discusses the pharmacology of these agents, to better understand how they may act to mitigate attacks and to provide some practical formulations for how to use them in the clinic for the benefit of patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17920542     DOI: 10.1016/j.nurt.2007.07.008

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   7.620


  50 in total

Review 1.  Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders.

Authors:  R Gold; F Buttgereit; K V Toyka
Journal:  J Neuroimmunol       Date:  2001-07-02       Impact factor: 3.478

2.  Effects of pulse methylprednisolone on inflammatory mediators in peripheral blood, synovial fluid, and synovial membrane in rheumatoid arthritis.

Authors:  P P Youssef; D R Haynes; S Triantafillou; A Parker; J R Gamble; P J Roberts-Thomson; M J Ahern; M D Smith
Journal:  Arthritis Rheum       Date:  1997-08

Review 3.  Following the TRAIL to apoptosis.

Authors:  Bharti R Chaudhari; Richard F Murphy; Devendra K Agrawal
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

4.  Corticosteroid treatment of experimental autoimmune encephalomyelitis in the Lewis rat results in loss of V beta 8.2+ and myelin basic protein-reactive cells from the spinal cord, with increased total T-cell apoptosis but reduced apoptosis of V beta 8.2+ cells.

Authors:  P A McCombe; I Nickson; Z Tabi; M P Pender
Journal:  J Neuroimmunol       Date:  1996-11       Impact factor: 3.478

Review 5.  Distinguishing polyarteritis nodosa from microscopic polyangiitis and implications for treatment.

Authors:  L Guillevin; F Lhote
Journal:  Curr Opin Rheumatol       Date:  1995-01       Impact factor: 5.006

6.  Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis.

Authors:  D Barnes; R A Hughes; R W Morris; O Wade-Jones; P Brown; T Britton; D A Francis; G D Perkin; P Rudge; M Swash; H Katifi; S Farmer; J Frankel
Journal:  Lancet       Date:  1997-03-29       Impact factor: 79.321

Review 7.  Corticosteroids or ACTH for acute exacerbations in multiple sclerosis.

Authors:  G Filippini; F Brusaferri; W A Sibley; A Citterio; G Ciucci; R Midgard; L Candelise
Journal:  Cochrane Database Syst Rev       Date:  2000

8.  High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations.

Authors:  L Durelli; D Cocito; A Riccio; C Barile; B Bergamasco; G F Baggio; F Perla; M Delsedime; G Gusmaroli; L Bergamini
Journal:  Neurology       Date:  1986-02       Impact factor: 9.910

9.  Glucocorticoid receptor-like antigen in lymphoma cell membranes: correlation to cell lysis.

Authors:  B Gametchu
Journal:  Science       Date:  1987-04-24       Impact factor: 47.728

10.  First trimester exposure to corticosteroids and oral clefts.

Authors:  Pierre Pradat; Elisabeth Robert-Gnansia; Gian Luca Di Tanna; Aldo Rosano; Alessandra Lisi; Pierpaolo Mastroiacovo
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2003-12
View more
  12 in total

Review 1.  Corticosteroids and plasma exchange in multiple sclerosis.

Authors:  Hayretin Tumani
Journal:  J Neurol       Date:  2008-12       Impact factor: 4.849

Review 2.  Uhthoff's phenomena in MS--clinical features and pathophysiology.

Authors:  Teresa C Frohman; Scott L Davis; Shin Beh; Benjamin M Greenberg; Gina Remington; Elliot M Frohman
Journal:  Nat Rev Neurol       Date:  2013-06-04       Impact factor: 42.937

3.  Deferiprone modulates in vitro responses by peripheral blood T cells from control and relapsing-remitting multiple sclerosis subjects.

Authors:  Matthew E Sweeney; Joyce G Slusser; Sharon G Lynch; Stephen H Benedict; Sharon L Garcia; Laura Rues; Steven M LeVine
Journal:  Int Immunopharmacol       Date:  2011-07-30       Impact factor: 4.932

4.  Symptomatic therapy in multiple sclerosis.

Authors:  Teresa C Frohman; Wanda Castro; Anjali Shah; Ardith Courtney; Jeffrey Ortstadt; Scott L Davis; Diana Logan; Thomas Abraham; Jaspreet Abraham; Gina Remington; Katherine Treadaway; Donna Graves; John Hart; Olaf Stuve; Gary Lemack; Benjamin Greenberg; Elliot M Frohman
Journal:  Ther Adv Neurol Disord       Date:  2011-03       Impact factor: 6.570

5.  Efficacy of Different Durations of Intravenous Methylprednisolone Treatment in Relapses of Multiple Sclerosis.

Authors:  Uğur Kulu; Bedile İrem Tiftikcioğlu; Yaşar Zorlu; Mustafa Çetiner; Ufuk Şener; Gamze Tuna; Güldal Kirkali
Journal:  Noro Psikiyatr Ars       Date:  2016-03-28       Impact factor: 1.339

Review 6.  Treatment of acute relapses in multiple sclerosis.

Authors:  Regina Berkovich
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

7.  Management of acute exacerbations in multiple sclerosis.

Authors:  Daniel Ontaneda; Alex D Rae-Grant
Journal:  Ann Indian Acad Neurol       Date:  2009-10       Impact factor: 1.383

8.  The effect of pulse methylprednisolone plus theophylline treatment on clinical, pulmonary and inflammatory markers in relapses of multiple sclerosis.

Authors:  Pervin Işeri; Ilknur Başyiğit; Ciğdem Ozerdem; Hüseyin Başyiğit; Hüsnü Efendi; Füsun Yıldız
Journal:  Balkan Med J       Date:  2013-03-01       Impact factor: 2.021

Review 9.  Monomethyl Fumarate (MMF, Bafiertam) for the Treatment of Relapsing Forms of Multiple Sclerosis (MS).

Authors:  Amnon A Berger; Emily R Sottosanti; Ariel Winnick; Jonathan Izygon; Kevin Berardino; Elyse M Cornett; Alan D Kaye; Giustino Varrassi; Omar Viswanath; Ivan Urits
Journal:  Neurol Int       Date:  2021-05-19

10.  Current options for the treatment of optic neuritis.

Authors:  John H Pula; Christopher J Macdonald
Journal:  Clin Ophthalmol       Date:  2012-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.